Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Профилактика тромботических осложнений с помощью Фрагмина у онкологических больных, получавших химиотерапию
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Полный текст
Список литературы
1. Prandoni P, Lensing A, Cogo A et al. The long-term clinical course of acute deep vein thrombosis. Ann Intern Med 1996: 125: 1–7.
2. Smorenburg SM, Hutten BA, Prins MN. Should patients with venous thromboembolism and cancer be treated differently? Haemostasis 1999; 29 (suppl): 91–7.
3. Levine MN, Lee AY, Kakkar AK Thrombosis and cancer. American Society of Clinical Oncology, 41 Annual Meeting 2005; 13–17: 748–77.
4. Arcelus JI. Recognizing the risk of VTE in surgical patients. International Surgical Thrombosis Meeting «Optimizing VTE Management in surgical patients» (abstract). Greece, 2007.
5. Bromberg ME, Cappello M. Cancer and blood coagulation: molecular aspects. Cancer 1999; 3: 132–8.
6. Schmitt M, Kuhn W, Hardee N, Grief H. Thrombophilic state in breast cancer. Seminars in double-blind study to compare the efficacy and safety of postoperative fondaparinux (Arixtra) and preoperative dalteparin in the prevention of venous thromboembolism after high risk abdominal surgery: the PEGASUS Study (abstract). Blood 2003; 102: 15a.
7. Weitz JC, Israel VK, Waisman JR et al. Chemotherapy – induced activation of hemostasis: effect of a low molecular weight heparin (dalteparin sodium) on plasma markers of hemostatic activation. J Thromb Haemost 2002; 88 (2): 213–20.
8. Levine MN. Prevention of thrombotic disorders in cancer patients undergoing chemotherapy. Thrombos Haemostas 1997; 78: 133–6.
9. Kakkar AK, Williamson RCN. Prevention of venous thromboembolism in cancer patients. Seminars in Thrombosis and Haemostasis; 1999: 25 (2): 239–43.
10. Kakkar AK, Haas S, Walsh D et al. Compliance with recommended prophylxis for venous thromboembolism: improving the use and rate of uptake of clinical practice guidelines. J Thromb Haemost 2004; 2: 221–7.
2. Smorenburg SM, Hutten BA, Prins MN. Should patients with venous thromboembolism and cancer be treated differently? Haemostasis 1999; 29 (suppl): 91–7.
3. Levine MN, Lee AY, Kakkar AK Thrombosis and cancer. American Society of Clinical Oncology, 41 Annual Meeting 2005; 13–17: 748–77.
4. Arcelus JI. Recognizing the risk of VTE in surgical patients. International Surgical Thrombosis Meeting «Optimizing VTE Management in surgical patients» (abstract). Greece, 2007.
5. Bromberg ME, Cappello M. Cancer and blood coagulation: molecular aspects. Cancer 1999; 3: 132–8.
6. Schmitt M, Kuhn W, Hardee N, Grief H. Thrombophilic state in breast cancer. Seminars in double-blind study to compare the efficacy and safety of postoperative fondaparinux (Arixtra) and preoperative dalteparin in the prevention of venous thromboembolism after high risk abdominal surgery: the PEGASUS Study (abstract). Blood 2003; 102: 15a.
7. Weitz JC, Israel VK, Waisman JR et al. Chemotherapy – induced activation of hemostasis: effect of a low molecular weight heparin (dalteparin sodium) on plasma markers of hemostatic activation. J Thromb Haemost 2002; 88 (2): 213–20.
8. Levine MN. Prevention of thrombotic disorders in cancer patients undergoing chemotherapy. Thrombos Haemostas 1997; 78: 133–6.
9. Kakkar AK, Williamson RCN. Prevention of venous thromboembolism in cancer patients. Seminars in Thrombosis and Haemostasis; 1999: 25 (2): 239–43.
10. Kakkar AK, Haas S, Walsh D et al. Compliance with recommended prophylxis for venous thromboembolism: improving the use and rate of uptake of clinical practice guidelines. J Thromb Haemost 2004; 2: 221–7.
Авторы
О.В.Сомонова, А.В.Маджуга, А.Л.Елизарова, Г.Н.Зубрихина
ГУ Российский онкологический научный центр им. Н.Н.Блохина РАМН, Москва
ГУ Российский онкологический научный центр им. Н.Н.Блохина РАМН, Москва
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.